El daño de la denominación puede ser mayor que el de la condición | 06 SEP 18
Dejar de denominar "cáncer" a condiciones de bajo riesgo
Quitar la etiqueta del cáncer en condiciones de bajo riesgo que es poco probable que causen daño si no se tratan puede ayudar a reducir el sobrediagnóstico y el sobretratamiento
Nickel B, Barratt A, Copp T, Moynihan R, McCaffery K. Words do matter: a systematic review on how different terminology for the same condition influences management preferences. BMJ Open2017;7:e014129. doi:10.1136/bmjopen-2016-014129. pmid:28698318
Esserman LJ, Thompson IM, Reid B, et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol2014;15:e234-42. doi:10.1016/S1470-2045(13)70598-9. pmid:24807866
Allegra CJ, Aberle DR, Ganschow P, et al. NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS). NIH Consens State Sci Statements2009;26:1-27.pmid:19784089
Brito JP, Morris JC, Montori VM. Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours. BMJ2013;347:f4706. doi:10.1136/bmj.f4706. pmid:23982465
Østerø Í Jákupsstovu J, Brodersen J. Do men with lower urinary tract symptoms have an increased risk of advanced prostate cancer?BMJ2018;361:k1202. doi:10.1136/bmj.k1202. pmid:29724877
Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst2010;102:605-13. doi:10.1093/jnci/djq099. pmid:20413742
Furuya-Kanamori L, Bell KJ, Clark J, Glasziou P, Doi SA. Prevalence of Differentiated thyroid cancer in autopsy studies over six decades: a meta-analysis. J Clin Oncol2016:JCO677419. doi:10.1200/JCO.2016.67.7419. pmid:27601555
Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide thyroid-cancer epidemic? the increasing impact of overdiagnosis. N Engl J Med2016;375:614-7. doi:10.1056/NEJMp1604412. pmid:27532827
Ito Y, Miyauchi A, Oda H. Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials. Eur J Surg Oncol2018;44:307-15. doi:10.1016/j.ejso.2017.03.004. pmid:28343733
Jeon MJ, Kim WG, Kwon H, et al. Clinical outcomes after delayed thyroid surgery in patients with papillary thyroid microcarcinoma. Eur J Endocrinol2017;177:25-31. doi:10.1530/EJE-17-0160. pmid:28432268
Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol2015;1:888-96. doi:10.1001/jamaoncol.2015.2510. pmid:26291673
Hamdy FC, Donovan JL, Lane JA, et al., ProtecT Study Group. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med2016;375:1415-24. doi:10.1056/NEJMoa1606220. pmid:27626136
Francis A, Fallowfield L, Rea D. The LORIS trial: addressing overtreatment of ductal carcinoma in situ. Clin Oncol (R Coll Radiol)2015;27:6-8. doi:10.1016/j.clon.2014.09.015. pmid:25445552
Elshof LE, Tryfonidis K, Slaets L, et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ—the LORD study. Eur J Cancer2015;51:1497-510. doi:10.1016/j.ejca.2015.05.008. pmid:26025767
ClinicalTrials.gov. Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for low risk DCIS. 2017 https://clinicaltrials.gov/ct2/show/NCT02926911.
Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ2005;331:481. doi:10.1136/bmj.38516.649537.E0. pmid:16081427
Mocellin S, Nitti D. Cutaneous melanoma in situ: translational evidence from a large population-based study. Oncologist2011;16:896-903. doi:10.1634/theoncologist.2010-0340. pmid:21632457
Patz EF Jr., Pinsky P, Gatsonis C, et al., NLST Overdiagnosis Manuscript Writing Team. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med2014;174:269-74. doi:10.1001/jamainternmed.2013.12738. pmid:24322569
Schwartz LM, Woloshin S, Fowler FJ Jr., Welch HG. Enthusiasm for cancer screening in the United States. JAMA2004;291:71-8. doi:10.1001/jama.291.1.71. pmid:14709578
Waller J, Osborne K, Wardle J. Enthusiasm for cancer screening in Great Britain: a general population survey. Br J Cancer2015;112:562-6. doi:10.1038/bjc.2014.643. pmid:25535731
Kiviniemi MT, Hay JL. Awareness of the 2009 US Preventive Services Task Force recommended changes in mammography screening guidelines, accuracy of awareness, sources of knowledge about recommendations, and attitudes about updated screening guidelines in women ages 40-49 and 50+. BMC Public Health2012;12:899. doi:10.1186/1471-2458-12-899. pmid:23092125
Sirovich BE, Woloshin S, Schwartz LM. Screening for cervical cancer: will women accept less?Am J Med2005;118:151-8. doi:10.1016/j.amjmed.2004.08.021. pmid:15694900
Silver MI, Rositch AF, Burke AE, Chang K, Viscidi R, Gravitt PE. Patient concerns about human papillomavirus testing and 5-year intervals in routine cervical cancer screening. Obstet Gynecol2015;125:317-29. doi:10.1097/AOG.0000000000000638. pmid:25568994
Gigerenzer G, Mata J, Frank R. Public knowledge of benefits of breast and prostate cancer screening in Europe. J Natl Cancer Inst2009;101:1216-20. doi:10.1093/jnci/djp237. pmid:19671770
Fagerlin A, Zikmund-Fisher BJ, Ubel PA. Cure me even if it kills me: preferences for invasive cancer treatment. Med Decis Making2005;25:614-9. doi:10.1177/0272989X05282639. pmid:16282212
Omer ZB, Hwang ES, Esserman LJ, Howe R, Ozanne EM. Impact of ductal carcinoma in situ terminology on patient treatment preferences. JAMA Intern Med2013;173:1830-1. doi:10.1001/jamainternmed.2013.8405. pmid:23978843
Loeb S, Folkvaljon Y, Makarov DV, Bratt O, Bill-Axelson A, Stattin P. Five-year nationwide follow-up study of active surveillance for prostate cancer. Eur Urol2015;67:233-8. doi:10.1016/j.eururo.2014.06.010. pmid:24993868
Orom H, Underwood W 3rd., Biddle C. Emotional distress increases the likelihood of undergoing surgery among men with localized prostate cancer. J Urol2017;197:350-5. doi:10.1016/j.juro.2016.08.007. pmid:27506694
Egger SJ, Calopedos RJ, O’Connell DL, et al. Long-term psychological and quality-of-life effects of active surveillance and watchful waiting after diagnosis of low-risk localised prostate cancer. Eur Urol2018;73:859-67. doi:10.1016/j.eururo.2017.08.013. pmid:28851582